Grifols's yield on cost for the quarter that ended in Jun. 2022 was 0.00.
The historical rank and industry rank for Grifols's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, Grifols's highest Yield on Cost was 2.51. The lowest was 0.00. And the median was 1.07.
Competitive Comparison
For the Drug Manufacturers - General subindustry, Grifols's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grifols 5-Year Yield-on-Cost % Distribution
For the Drug Manufacturers industry and Healthcare sector, Grifols's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Grifols's 5-Year Yield-on-Cost % falls into.
Grifols 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Grifols is calculated as
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Grifols 5-Year Yield-on-Cost % Related Terms
Thank you for viewing the detailed overview of Grifols's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 77% of sales in 2021. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics is now roughly 15% of revenue following the Novartis and Hologic deals.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.05(0.6%) Volume: 489,829 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:GRFS has been successfully added to your 
